No plans to get into vaccine production as it requires separate manufacturing infra: Sun Pharma


PTI, Jun 13, 2021, 1:04 PM IST

New Delhi: Sun Pharma has no immediate plans to enter into vaccine production as getting into the vertical would require an altogether different manufacturing set-up, as per a top company official.

The Mumbai-based company, which is strong in various generic therapeutic segments, is eyeing biosimilars to fuel its future growth.

“I think our preliminary assessment indicates that vaccines will require a dedicated manufacturing facility and it cannot be produced in a facility where we are making multiple other products,” Sun Pharmaceutical Industries Managing Director Dilip Shanghvi said in a call with analysts.

The billionaire industrialist noted that for getting into vaccine production, a completely new set of manufacturing infrastructure is required.

“So, that”s broadly our understanding. So, we currently don”t have any facility which we are looking at for producing vaccines,” Shanghvi said.

On the biosimilar front, he noted that the drug firm is looking to develop a range of such products.

“We are evaluating development of some biosimilars which can be classified amongst the third wave of biosimilars,” Shanghvi said while clarifying that the company is looking at 2030 kind of timeline for such products to hit the market.

A biosimilar is a product which is similar to another already approved biological medicine.

The company is looking at products which have significant future patent expiry dates so that it could be amongst the first firms to get initial approvals, Shanghvi said.

“That”s the focus and priority. And that”s not the only (thing), there are multiple priorities, and also (we are) trying to find a way by which we can leverage our presence in the market so that we can successfully build a biosimilars portfolio,” he added.

He noted that the development of the biosimilars would not be a ”big drain” on the company’s cash flow and profitability.

Commenting on the US business, he said the drug firm’s current generic pipeline for the US market includes 94 abbreviated new drug applications (ANDAs) and nine new drug applications (NDAs) awaiting approval with the US FDA.

In 2020-21, the company launched around 18 new products in the US.

On business outlook, Shanghvi noted: “Given the uncertainties of the pandemic in the near term, we are refraining from giving guidance for FY22. However, all our businesses are well positioned and our endeavour will be to grow the business, notwithstanding the near term uncertainties related to COVID-19.”

The drug firm’s revenue from operations stood at Rs 33,498 crore in 2020-21.

Commenting on the company’s Halol plant, which has been under the USFDA radar for the last few years, Shanghvi said the drug firm is waiting for the regulator to inspect the facility.

“We have requested for an inspection. Now, I think it’s up to them to inspect the facility. And hopefully this time we should be able to clear it successfully, that”s the focus,” he added.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

Rishabh Pant becomes most expensive IPL buy at Rs 27 crore, Iyer fetches Rs 26.75 crore deal

JD(S) first family avoids discussion on Channapatna bypoll debacle

BJP, JD(S) leaders helped win Channapatna bypoll: DK Shivakumar

Virat Kohli doesn’t have anything to prove, his contribution is unparalleled: Kapil Dev

IPL auction: Arshdeep bought by Punjab Kings for Rs 18 crore, Rabada goes to GT for Rs 10.75 crore

‘King and The Prince’: Tons by young Jaiswal, veteran Kohli put India in winning position

Malayalam actress changes her stance, to proceed with sexual harassment cases against actors

Related Articles More

Malayalam actress changes her stance, to proceed with sexual harassment cases against actors

People taught befitting lesson to those talking about breaking country: Kangana on Maharashtra polls

Parliamentary panel to examine issue of lateral entry

Fresh plea in SC seeks probe into US indictment of Gautam Adani

Sambhal violence orchestrated by BJP, govt to divert attention from poll rigging: Akhilesh

MUST WATCH

Prakash Belawadi

Naxal Leader Vikram Gowda

Christmas Cake Fruit Mixing

DK Shivakumar

Rose Cultivation


Latest Additions

Rishabh Pant becomes most expensive IPL buy at Rs 27 crore, Iyer fetches Rs 26.75 crore deal

JD(S) first family avoids discussion on Channapatna bypoll debacle

BJP, JD(S) leaders helped win Channapatna bypoll: DK Shivakumar

Virat Kohli doesn’t have anything to prove, his contribution is unparalleled: Kapil Dev

IPL auction: Arshdeep bought by Punjab Kings for Rs 18 crore, Rabada goes to GT for Rs 10.75 crore

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.